Trial Profile
Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV in Brazilian Transgender Women
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jul 2022
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir (Primary) ; Estradiol valerate; Spironolactone
- Indications HIV infections
- Focus Therapeutic Use
- Acronyms PrEParadas
- 11 Jul 2022 Results of a sub-study assessing the impact of feminizing hormone therapy on tenofovir and emtricitabine plasma pharmacokinetics published in the Journal of Antimicrobial Chemotherapy
- 21 Jul 2021 Results evaluating the impact of FHT on PrEP pharmacokinetics (PK) in PrEParadas Study presented at the 11th International AIDS Society Conference on HIV Science
- 21 Jul 2021 Status changed from recruiting to completed.